Dr. Drazer’s Google Scholar profile is here.

1. Ybe JA, Perez-Miller S, Niu Q, Coates DA, Drazer MW, Clegg ME. Light chain c-terminal region reinforces the stability of clathrin heavy chain trimers. Traffic. 2007; 8(8): 1101-10. PMID: 17555534.

2. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. Journal of Clinical Oncology. 2011; 29(13): 1736-43. PMID: 21444863.

3. Rosen A, Jayram G, Drazer MW, Eggener SE. Global trends in testicular cancer incidence and mortality. European Urology. 2011: 60(2): 374-9. PMID: 21612857.

4. Prasad SM*, Drazer MW*, Huo D, Hu JC, Eggener SE. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012; 307(16): 1692-4. PMID: 22535850.  *co-first authors

5. Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014; 120(10): 1491-8. PMID: 24523016.

6. Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates following the 2012 United States Preventive Services Task Force recommendation discouraging prostate-specific antigen (PSA)-based screening. Journal of Clinical Oncology. 2015; 33(22): 2416-23. PMID: 26056181.      

7. Drazer MW, Salama JK, Hahn OM, Weichselbaum RR, Chmura SJ. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Review of Anticancer Therapy. 2016;16(6):625-32. PMID: 27078719.

8. Sweis RF, Drazer MW, Ratain MJ. Analysis of impact of post-treatment biopsies in phase I clinical trials. Journal of Clinical Oncology. 2016; 34(4): 369-74. PMID: 26668350.

9. Drazer MW, Stadler WM. The role of testosterone in the treatment of castration resistant prostate cancer. The Cancer Journal: The Journal of Principles and Practice of Oncology. 2016; 22(5): 330-333. PMID 27749326.

10. Feurstein S, Drazer MW, Godley LA. Genetic predisposition to leukemia and other hematologic malignancies. Seminars in Oncology. 2016; (43): 598-608. PMID 27899193.

11. Drazer MW, Feurstein S, West AH, Jones MF, Churpek JE, Godley LA. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016; 16: 1800-1831. PMID: 27471235.

12. Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty CK, Ceballos-López AA, Raca G, Lingen MW, Li Z, Segal JP, Churpek JE, Godley LA. Prognostic tumor sequencing panels frequently identify germline variants associated with hereditary myeloid malignancies. Blood Advances. 2018. PMID: 29365323.

13. Tawana K, Drazer MW, Churpek JE. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: Are we there yet? Leukemia. 2018. PMID: 29483711.

14. Walsh MF, Ritter DI, Kesserwan C, Sonkin D, Chakravarty D, Chao E, Ghosh R, Kemel Y, Wu G, Lee K, Kulkarni S, Hedges D, Mandelker D, Ceyhan-Birsoy O, Luo M, Drazer MW, Zhang L, Offit K, Plon SE. Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. Human Mutation. 2018. PMID: 30311369.

15. Drazer MW, Sweis RF. Low clinical adoption of tumor genomic profiling: cause for concern? Journal of Medical Economics. 2018. PMID: 29708449.

16. Akpan IJ, Osman AEG, Drazer MW, Godley LA. Hereditary myelodysplastic syndrome and acute myeloid leukemia: diagnosis, questions, and controversies. Current Hematologic Malignancy Reports. 2018. PMID: 30259338.

17. Roloff GW, Godley LA, Drazer MW. Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies. Genetics in Medicine. 2021. PMID 32807974.

18. Borst S, Camire RM, Drazer MW, Godley LA, French DL, Poncz M, Gadue P. Comparative study of the molecular mechanism of inherited thrombocytopenia resulting from monoallelic mutations in ETV6 or RUNX1 using the human pluripotent stem cell model. Stem Cell Reports. 2021. PMID 34019812.

19. Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, Bodor C, Cantor A, Cazzola M, Degelman E, Dinardo C, Duployez N, Favier R, Fröhling S, Fitzgibbon J, Klco J, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan N, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yuan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown AL. The RUNX1 database: a RUNX1 genomics database for mutation data aggregation, analysis, and sharing. Haematologica. 2021. PMID 34233450.

20. Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM, Larson RA. Therapy-related myeloid neoplasms in 109 patients following radiation monotherapy. 2021. Blood Advances. PMID 34492705. 

21. Roloff GW, Drazer MW, Godley LA. Inherited susceptibility to hematopoietic malignancies in the era of precision oncology. JCO Precision Oncology. 2021. PMID: 34994594.

22. White MG, Drazer MW, Eng OS. Gastrointestinal surgical emergencies in the neutropenic immunocompromised patient. Journal of Gastrointestinal Surgery. 2021. PMID: 34506017.

23. Feurstein S, Drazer MW, Godley LA. Germline predisposition to hematopoietic malignancies. Human Molecular Genetics. 2021. PMID: 34100074.

24. Wang P, Segal J, Drazer MW, Venkataraman G, Arber D, Gurbuxani S. NPM1 exon 5 mutations in acute myeloid leukemia: implications in diagnosis and minimal residual disease monitoring. 2022. eJHaem. PMID 36051025.

25. Drazer MW*, Homan CC*, Yu K*, King-Smith SL, Pozsgai MJ, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Bodor C, Cantor A, Cazzola M, Degelman E, Dinardo C, Duployez N, Favier R, Fröhling S, Fitzgibbon J, Klco J, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan N, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yuan B, Liu P, Schreiber AW, Hahn CN, Brown AL, Scott HS, Godley LA. Clonal hematopoiesis in individuals with ANKRD26 or ETV6 germline mutations. 2022. Blood Advances. PMID 35537115.

26. Feurstein SK, Trottier AM, Estrada-Merly N, Pozsgai MJ, McNeely KE, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu ZH, Sobecks RM, Spellman SR, Saber W, Godley LA. Germline predisposition variants occur in myelodysplastic syndrome patients of all ages. 2022. Blood. PMID 35969835.

27. Roloff GW, Wen F, Ramsland AS, Artz AS, Kosuri S, Stock W, Odenike O, Larson RA, Liu H, Godley LA, Thirman MJ, Patel AA, Daugherty CK, Duvall AS, Nawas MT, Dworkin E, Wool GD, Fitzpatrick C, Segal JP, Wang P, Drazer MW. Clinical and molecular responses of AML harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. 2023. Haematologica. PMID 36655425.

28. Berger Y, Gadiraju M, Dhiman A, Gilliam K, Rose B, Chen H, Helgeson M, Eng OS, Husain A, Drazer MW, Kindler HL, Churpek JE, Turaga K. Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation. 2023. Cancer. PMID 37042570.

29. Mitchell OD, Gilliam K, Del Gaudio D, McNeely KE, Smith S, Acevedo M, Gaduraju M, Hodge R, Ramsland AS, Segal JP, Das S, Bryan DS, Tawde S, Galasinski S, Wang P, Tjota MY, Husain AN, Armato III S, Donington J, Ferguson MK, Turaga K, Churpek JE, Kindler HL, Drazer MW. Frequency of incidental pathogenic and likely pathogenic germline variants detected via tumor-only mesothelioma genomic profiling. JAMA Network Open. 2023. PMID 37556141.

30. Roloff GW, Shaw R, O’Connor TE, Hathaway F, Drazer MW. Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies. 2023. Journal of Genetic Counseling. PMID 36642751.

31. Ramsland A, Cannova J, Wen F, Khosravi Z, McNeely KE, Canham LE, Roloff GW, Drazer MW. Inherited predisposition to hematopoietic malignancies: advances made in the diagnosis and management of hereditary hematopoietic malignancies in the era of next generation sequencing technologies. Advances in Oncology. 2023.

32. Hamidi A, Roloff G, Shaw R, Drazer MW. Clinical guideline variability in the diagnosis and care of people at risk for hereditary hematopoietic malignancy syndromes. Leukemia & Lymphoma. 2023. PMID 37294121.

33. Homan CC*, Drazer MW*, Yu K*, Lawrence DM, Feng J, Arriola-Martinez LA, Poszgai MJ, McNeely KE, Ha TT, Venugopal P, Arts P, King-Smith S, Cheah JJ, Armstrong M, Wang P, Bödör C, Cantor AB, Cazzola M, Degelman ES, DiNardo CD, Duployez N, Favier R, Fröhling S, Rio-Machin A, Klco JM, Krämer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Georges N, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff HY, Ripperger T, Schulte RR, Tawana K, Velloso E, Benedict Y, Kim EMK, Sood R, Hsu AP, Holland SM, Phillips K, Poplawski N, Babic M, Wei AH, Forsyth CJ, Mar Fan H, Lewis I, Cooney JP, Susman R, Fox LC, Blombery P, Singhal D, Hiwase DK, Phipson B, Schreiber AW, Hahn CN, Scott HS, Liu PP, Godley LA, Brown AL. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germ line RUNX1, GATA2, and DDX41 variants. Blood Advances. 2023. PMID 37406166.

34. Johnston H, Rahmani Youshanlouei H, Osei C, Patel AA, DuVall AS, Wang P, Wanjari P, Segal JP, Venkataraman G, Cheng JX, Gurbuxani S, Lager AM, Fitzpatrick C, Thirman MJ, Nawas MT, Liu H, Drazer MW, Odenike O, Larson RA, Stock W, Saygin C. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. 2023. Blood Advances. PMID 38039510.

In the Press, Patient Advocacy, and Education:

1. The New York Times, “When Should Men Stop PSA Testing?”, 2011. (link)

2. The New York Times, “Screening Prostates at Any Age”, 2011. (link)

3. The New York Times, “Older Men are Still Being Screened for Prostate Cancer”, 2012. (link)

4. The New York Times, “Older Men are Still Being Overtested for Prostate Cancer”, 2016. (link)

5. Damon Runyon Cancer Research Foundation News, “Solving the Mystery of a Rare Blood Cancer Leads to a Cure”, 2019. (link)

6. ASH Carrier Advisory Committee: Genomics of hereditary blood disorders, 2021

7. ASH Carrier Advisory Committee: Precision Hematology, 2022

8. Leukemia & Lymphoma Society: Beyond Your Diagnosis, 2022 (link)

9. ASH Clinical News: To Test or Not To Test? 2022 (link)

10. Blood Podcast discussing our 2022 manuscript (with the Godley group) in Blood detailing the prevalence of hereditary hematopoietic disorder-linked germline variants in the setting of stem cell transplant (link)